The Market Is Underestimating The Potential Of Aradigm's Lead Product Candidate
- Aradigm's lead product candidate, Pulmaquin, is in Phase III studies and has been granted a Fast Track designation by the FDA.
- The company already has a licensing agreement in place for its lead product candidate with Spanish company Grifols S.A.
- The licensing agreement with Grifols will enable Pulmaquin to reach full potential, if approved.
- Based on the potential of Pulmaquin alone, Aradigm looks significantly undervalued.
6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity
- Aradigm has a unique pipeline in development targeting undertreated respiratory diseases.
- There is almost no coverage to be found on Aradigm. Wall Street has yet to discover this company, which is rare for a Phase III biotech stock.
- Aradigm’s excellent financials, partnership with a major pharmaceutical company and stable share price significantly reduce downside risk.
- Aradigm looks severely undervalued. This reduces downside risk too, and amplifies upside potential.
Thu, Sep. 4, 8:16 AM
Thu, Sep. 4, 7:20 AM
- The FDA designates Aradigm Corp's (NASDAQ:ARDM) Pulmaquin (ciprofloxacin) Fast Track for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE) patients with chronic lung infections with Pseudomonas aeruginosa. The product candidate is currently in Phase 3 clinical trials.
- Ciprofloxacin is a widely-prescribed broad spectrum antibiotic. Pulmaquin is a dual release formulation consisting of a mixture of liposome encapsulated and unencapsulated ciprofloxacin. It is being evaluated as an inhaled formulation in two ongoing Phase 3 trials.
Thu, Aug. 7, 8:28 AM
Thu, Aug. 7, 7:56 AM
Mon, Jun. 23, 7:39 AM
- The first patient has been dosed in Aradigm's (ARDM) ORBIT-4 Phase 3 clinical trial evaluating Pulmaquin (inhaled ciprofloxacin) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). The primary endpoint of the 255-patient 48-week double-blind placebo-controlled study is superiority versus placebo measured by time to first pulmonary exacerbation.
- The FDA designated ciprofloxacin a Qualified Infectious Disease Product last month. Among the incentives is an additional five year extension of Hatch-Waxman exclusivity after regulatory approval.
Aug. 28, 2013, 2:20 PM
- Grifols (GRFS -0.9%) buys 35% of Aradigm (ARDM.OB) for $26M in a deal to develop Aradigm's formulations of inhaled ciproflaxin for the treatment of severe respiratory diseases.
- GRFS will take on all development and clinical expenses of he drug, up to a maximum of $65M for the non-cystic fibrosis bronchiectasis indication. There is currently no drug specifically approved for the treatment of this condition.
- In addition, ARDM.OB is entitled to receive cash payments of up to $25M upon achievement of development milestones.
- ARDM.OB was awarded orphan drug designation for BE in the U.S., and has completed Phase IIb clinical trials with the inhaled ciproflaxin - Pulmaquin and LipoQuin.
- Existing ARDM.OB shareholders, including Tavistock Life Sciences Company and accounts managed by First Eagle Investment Management and new investor Great Point Partners, co-invested in the stock purchase, buying an additional $15.4M in ARDM.OB stock.
Jul. 16, 2013, 2:42 PMGrifols (GRFS -1.6%) says that Aradigm (ARDM.OB) has received shareholder approval for its license agreement giving GRFS access to Aradigm's proprietary formulations of inhaled ciprofloxacin, which is used for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis. In conjunction with the licensing agreement, GRFS will acquire 35% of Aradigm's common stock at a price per share of $0.124 for a total investment of approximately $26M. | 1 Comment
ARDM vs. ETF Alternatives
Other News & PR